Sugi Predict

Sugi Predict / Targets / PLA2G10

PLA2G10

Group 10 secretory phospholipase A2 · O15496 · PLA2G10 on Sugi Atlas →

30,280 patent compounds predicted against PLA2G10, 15,249 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL818717 SCHEMBL818717 0.70 8/20
SCHEMBL818585 SCHEMBL818585 0.85 7/20
Varespladib Methyl Varespladib Methyl (SCHEMBL25678) 0.83 7/20
SCHEMBL818840 SCHEMBL818840 0.53 7/20
SCHEMBL818386 SCHEMBL818386 0.52 7/20
SCHEMBL435668 SCHEMBL435668 0.51 7/20
Varespladib Varespladib (SCHEMBL26726) 1.00 6/20
SCHEMBL818498 SCHEMBL818498 0.79 6/20
SCHEMBL435626 SCHEMBL435626 0.51 6/20
SCHEMBL818733 SCHEMBL818733 0.50 6/20
SCHEMBL436567 SCHEMBL436567 0.43 6/20
SCHEMBL817908 SCHEMBL817908 1.00 5/20
SCHEMBL819141 SCHEMBL819141 1.00 5/20
SCHEMBL818631 SCHEMBL818631 0.90 5/20
SCHEMBL819886 SCHEMBL819886 0.86 5/20
SCHEMBL818556 SCHEMBL818556 0.83 5/20
SCHEMBL819062 SCHEMBL819062 0.80 5/20
SCHEMBL819398 SCHEMBL819398 0.79 5/20
SCHEMBL819436 SCHEMBL819436 0.79 5/20
SCHEMBL818067 SCHEMBL818067 0.78 5/20

Clinical trials — most relevant to PLA2G10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Effects of Omega-3 Fatty Acids on the Human Gene Expression PHASE4COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis PHASE1/PHASE2COMPLETED
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT PHASE2COMPLETED
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide PHASE1COMPLETED
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Role of PLA2G1B During HIV Infection nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes nanCOMPLETED
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy nanRECRUITING
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations nanCOMPLETED
PET Imaging of DHA Metabolism nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
Molecular Markers of Human Sperm Function nanWITHDRAWN
LDL-Apheresis for FSGS CardioRenal Outcomes nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PLA2G10 binder may also engage these)

ProteinNameSimilarity
Q9QXX3 — 0.995 Q9QXX3 →
Q9QZT3 — 0.993 Q9QZT3 →
PLA2G2D Group IID secretory phospholipase A2 0.985 landscape →
Q9WVF6 — 0.982 Q9WVF6 →
PLA2G2E Group IIE secretory phospholipase A2 0.981 landscape →
P97391 — 0.975 P97391 →
Q9QUL3 — 0.975 Q9QUL3 →
P0DP54 — 0.974 P0DP54 →
Q8JFB2 — 0.974 Q8JFB2 →
PLA2G5 Phospholipase A2 group V 0.973 landscape →
Q9DF56 — 0.972 Q9DF56 →
Q2YHJ7 — 0.972 Q2YHJ7 →
Q56JZ2 — 0.972 Q56JZ2 →
P47711 — 0.971 P47711 →
Q90W39 — 0.971 Q90W39 →
Q71QE8 — 0.971 Q71QE8 →
Q800C1 — 0.971 Q800C1 →
P51433 — 0.971 P51433 →
Q6EER4 — 0.971 Q6EER4 →
Q6EER6 — 0.970 Q6EER6 →
O42187 — 0.970 O42187 →
Q8JIY9 — 0.970 Q8JIY9 →
P00615 — 0.970 P00615 →
P59071 — 0.970 P59071 →
Q6EAN6 — 0.970 Q6EAN6 →
Q4VRI5 — 0.970 Q4VRI5 →
Q1ZY03 — 0.970 Q1ZY03 →
A8E2V8 — 0.970 A8E2V8 →
Q910A0 — 0.970 Q910A0 →
Q2YHJ2 — 0.969 Q2YHJ2 →